DISTINCTIVE

seconD- line folfiri aflIbercept in proSpecTIvely stratified, anti-egfr resistaNt, metastatic coloreCTal  cancer patIents with ras validated wild typE status (distinctive)

AFLIBERCEPT POST ANTI-EGFR IN CCR

· Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE Trial

Phase2_study_of_second-line_FOLFIRI-aflibercept.pdf

Scarica il file